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Abstract Introduction: Frailty increases the risk of poor health outcomes, disability, hospitalization, and death
in older adults and affects 7%–12% of the aging population. Secondary impacts of frailty on psycholog-
ical health and socialization are significant negative contributors to poor outcomes for frail older adults.
Method: TheMyActive andHealthyAging (My-AHA) consortiumhas developed an information and
communications technology–based platform to support active and healthy aging through early detec-
tion of prefrailty and provision of individually tailored interventions, targeting multidomain risks for
frailty across physical activity, cognitive activity, diet and nutrition, sleep, and psychosocial activities.
Six hundred adults aged 60 years and older will be recruited to participate in a multinational, multisite
18-month randomized controlled trial to test the efficacy of the My-AHA platform to detect prefrailty
and the efficacy of individually tailored interventions to prevent development of clinical frailty in this
cohort. A total of 10 centers from Italy, Germany, Austria, Spain, United Kingdom, Belgium, Sweden,
Japan, South Korea, and Australia will participate in the randomized controlled trial.
Results: Pilot testing (Alpha Wave) of the My-AHA platform and all ancillary systems has been
completed with a small group of older adults in Europe with the full randomized controlled trial
scheduled to commence in 2018.
Discussion: TheMy-AHA study will expand the understanding of antecedent risk factors for clinical
frailty so as to deliver targeted interventions to adults with prefrailty. Through the use of an informa-
tion and communications technology platform that can connect with multiple devices within the
older adult’s own home, the My-AHA platform is designed to measure an individual’s risk factors
for frailty across multiple domains and then deliver personalized domain-specific interventions to
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the individual. The My-AHA platform is technology-agnostic, enabling the integration of new de-
vices and sensor platforms as they emerge.
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1. Introduction
Frailty is a precursor of and contributor to age-related dis-
eases [1–5] affecting 7%–12% of the adults aged 65 years
and older [5], with the occurrence of frailty increasing
with age and potentially reaching a prevalence of 45% in
those aged older than 85 years [6,7]. It has been suggested
that frailty develops when age-associated degenerative pro-
cesses overwhelm reserve capacity and plasticity processes
that maintain function of the nervous system and other phys-
iologic systems [5,8,9]. Overall, frailty represents the
vulnerability of aged population to adverse events as the
result of the subtle and progressive metabolic and physical
changes. Frailty confers a significantly increased risk for
poor health outcomes, incident disability, hospitalization,
and mortality [7,10–14]. Older adults experiencing frailty
are not acutely medically ill but are in a state of
compromised function and capacity arising from a
reduction in reserve capacity across multiple systems [15].
This loss of reserve capacity places the individual in a state
that is approaching the physiological threshold for symp-
tomatic clinical failure [15]. Therefore, frailty refers to a
state of reduced physiological function and capacity rather
than to a disease or clinical condition. An older adult in a
state of frailty is at increased risk of developing secondary
diseases, which then in turn exacerbate the level of frailty
experienced [4]. A frail older adult can be conceived of as
continually performing at his/her maximum capacity
without additional reserves to cope with additional stressors.
At the highest level of frailty, the person is increasingly
dependent on caregivers, highlighting the social impact of
frailty as the person progressively loses autonomy. This
loss of autonomy is associated with increased need for assis-
tance with mobility, self-care, and activities of daily living,
with an associated progressive loss of self-confidence, lead-
ing to social isolation, reduced physical activity, progressive
isolation, and decreased social interaction, further exacer-
bating the level of frailty experienced by the individual.
Therefore, early identification and intervention of frailty is
essential to prevent this deterioration.
The clinical diagnosis of frailty is based on the presence of
symptoms of physical weakness (including weak muscle
strength, slow gait speed, unintentional weight loss, malnutri-
tion or comorbidity, exhaustion, and low physical activity).
The diagnosis of frailty requires the presence of three or
more symptoms of the following: shrinking (weight loss or
sarcopenia), muscle weakness; poor energy and endurance,
motor slowing, and/or reduced level of physical activity [5].
The presence of three or more of these frailty criteria in an
older (.65 years) adult constitutes clinical frailty [5]. Individ-
uals presentingwith one or two symptoms are considered to be
in a prefrail stage [16]. The prefrail stage (1–2 Fried et al [5]
criteria) identifies a subset at high risk of progressing to frailty.
A fundamental weakness of current clinical frailty
criteria [5] is that they remain specific to physical frailty
and do not encompass the potential for frailty in other do-
mains (e.g., cognitive, psychological, social, and so forth).
Hence, the clinical criteria do not fully reflect the theoretical
construct of frailty as a weakness in capacity across multiple
systems. An additional challenge to conceptualizing pre-
frailty is in the relationship between frailty and other
aging-related diagnostic constructs (e.g., preclinical demen-
tia, preclinical Parkinson’s disease, mild cognitive impair-
ment [MCI], and so forth). The construct of frailty refers
to a state of compromised function and capacity arising
from a reduction in reserve capacity across multiple systems,
creating conceptualization challenges in differentiating
frailty from other aging-related syndromes involving a loss
of function and capacity. For example, MCI [17–19] is a
preclinical syndrome of dementia marked by subclinical
cognitive impairments. The more recently described phase
of preclinical dementia [20] precedes MCI and is marked
by biological changes in the brain associated with later
development of MCI and dementia. Neither preclinical de-
mentia nor MCI encompasses frailty as a symptom. Similar
phases of preclinical decline or deficits are also observed
with various psychological and psychiatric conditions,
including schizophrenia, bipolar disorders, as well as
mood disturbances and various anxiety-related disorders.
If frailty is considered to represent a state of vulnerability
in an aging individual to adverse events as a result of subtle
and progressive metabolic and physical changes, then the
construct of frailty represents either: (1) a fully independent
diagnostic entity; or, (2) an umbrella term encompassing all
aging-related vulnerabilities, from which specific diagnostic
constructs emerge (e.g., MCI). The relationship between
frailty and other aging-related disorders is an important
consideration that ultimately determines the clinical features
of frailty and prefrailty. If frailty is considered to be an um-
brella term, then the diagnostic features for specific condi-
tions can be incorporated into frailty subtypes. If, however,
frailty is considered to be independent of other aging-
related disorders, then the presence of clinical features of
other aging-related disorders precludes a diagnosis of frailty.
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1.1. Overall approach of the My Active and Healthy Aging
project
There has been a recent emergence of information and
communications technology (ICT)–based solutions to sup-
port active aging and tackle frailty, cognitive decline, and so-
cial isolation of older adults. Although these ICT-based
solutions have demonstrable value in reducing single risks
(e.g., fall risk, and so forth), a holistic approach integrating so-
lutions to multiple individual risk factors has not been devel-
oped to date. Furthermore, there is a need to provide tailored
interventions based on an analysis of the combined multiple
risks for each individual, rather than a specific intervention
offered to all individuals irrespective of their level of risk.
For example, balance training exercises offered to all older
adults rather than providing balance training selectively to
those at greatest risk of falls will result in low treatment effi-
cacy. With frailty representing a state of compromise across
multiple systems, it is necessary to tailor interventions to
meet the individual’s level of risk for frailty across these mul-
tiple systems (physical, cognitive, psychological, and social).
The My Active and Healthy Aging (My-AHA) project is
designed to support and promote active and healthy aging
by enabling early detection and minimization of multidimen-
sional frailty risks. Early risk detection of compromise will
occur across multiple domains of physical activity, cognitive
activity, diet and nutrition, sleep, and psychosocial activities.
The My-AHA project will map an individual’s frailty risk
profile across multiple domains to enable the implementation
and delivery of ICT-based interventions tailored and targeted
to identify risk profile for each individual. Interventions with
established efficacy in improving cognitive, physical, social,
and nutritional function in older adults will be deployed via
a purpose-built software platform (My-AHA platform) with
integrated hardware. The My-AHA platform is an ICT
network composed of the following: (a) a database that re-
cords data about the user (demographic, health status, habits,
and activity), (b) a decision support system that implements
the rules for assessing the risk of frailty-related problems
and the interventions addressed to reduce them, (c) a front
end (“dashboard”) designed for web and mobile applications,
and (d) connectors with third-party applications that can be
used to register data (e.g., physical activity monitoring
through wearable sensors) or support the proposed interven-
tions (e.g., cognitive games). The My-AHA platform is novel
in that it will enable the deployment of intervention packages
individually tailored tomeet the frailty risk profile for each in-
dividual. This approach will ensure maximal treatment effi-
cacy and response to treatment of prefrailty in older adults.
Currently, operational criteria for prefrailty exist only for
the physical domain, whereby older adults (.65 years) dis-
playing one or two of the five Fried et al [5] frailty criteria
are considered to be in a prefrail state [16]. The question
therefore remains as to whether frailty (and by extension pre-
clinical frailty) possesses domain-specific subtypes is defined
by physical weakness with secondary weaknesses in other
domains or is a multidimensional nondomain-specific weak-
ness. There are no validated operational criteria for prefrailty
(or frailty) in the domains of cognition, mood (psychologi-
cal), or social function. Consequently, although it is possible
that an individual may display prefrailty across multiple do-
mains, the capacity to determine prefrail status of an individ-
ual exists only for the physical domain. For the purposes of
participant recruitment, participants will be screened for pre-
frailty status in the physical domain (Table 1). For cognitive
and psychological measures, as there are existing validated
thresholds for clinically significant deficits, participants will
be screened to ensure that they are below the threshold for a
clinically significant deficit which would exceed the level
required for a prefrail state (Table 2). Assessment of level
of functioning across all domains (physical, cognitive, psy-
chological, and social) will be undertaken across the duration
of the trial, and this data will be used to later develop and vali-
date criteria for identifying prefrailty in nonphysical domains.
The primary outcome of this study is to determine the effi-
cacy of an individually tailored multidomain ICT-delivered
intervention package in prefrail older adults in improving phys-
ical, cognitive, psychological, and social function.Multiple sec-
ondaryoutcomeswill alsobeexaminedduring the courseof this
study: (1) that the My-AHA platform leads to a significant
reduction in risk for clinical physical frailty in prefrail older
adults; (2) to identify syndromic markers for prefrailty across
nonphysical domains of cognition, social activity, and psycho-
logical health, (3) to develop and validate of amultidimensional
model of prefrailty in older adults; and, (4) to provide evidence
of the efficacy of ICT platforms in delivering home-based sup-
portive care to older adults in the community.
2. Methods
2.1. Study Design
TheMy-AHA project is a multicenter, 18-month random-
ized controlled trial (RCT) (ClinicalTrials.gov identifier:
NCT03342976) involving centers from Europe, Australia,
and Asia. The RCTwill conform to Consolidated Standards
of Reporting Trials guidelines [21] and is designed to result
in the development of objective criteria for multidimensional
prefrailty (physical, cognitive, social, and psychological) as
well as undertake an evidence-based examination of the effi-
cacy of ICT-based platforms to deliver tailored interventions
to prevent decline into clinical frailty states. The design of
the assessment component of the study is illustrated in Fig. 1.
2.2. Selection of study participants: Inclusion and
exclusion criteria
Participants will be adults aged 60 years and older
meeting study inclusion criteria for physical prefrailty and
not meeting one or more of the study exclusion criteria
(Table 3) for clinically significant cognitive and/or mood
disturbance or for concomitant diseases. A total of 600
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participants will be recruited across 10 study centers (see
Table 4).
2.3. Randomization/treatment assignment
Participants are randomly allocated to one of two study
arms: Study Arm 1 (standard care Control group) and Study
Arm 2 (My-AHA intervention group). Randomization will
occur at each study site independently. Initial randomization
of participants at each site will occur using a simple random-
ization 1 (control):1 (intervention) ratio, with allocation of
participants to each treatment arm being undertaken using
on alternating allocation sequence based on order of entry
into the study. Once allocation of 20 participants has
occurred at each site, the study site coordinator will submit
to the RCT study coordinator demographic information
(gender, age, and education level) for the 20 participants re-
cruited and allocated to each study arm. The RCT study
coordinator will review the balance of participants across
study arms for these demographic variables within each
study site and vary allocation procedures for remaining
participant assignment to study arms to ensure equivalence
of study arms within each site.
2.4. Intervention program
At baseline, all participants undergo comprehensive
assessment of multidomain functions (Fig. 1, Table 5
and Section 2.5). These assessments are repeated at six
monthly intervals across the duration of the RCT (6, 12,
and 18-month time points). Data from these four assess-
ment points will be used to ascertain the effect of the
intervention program on the functional status of each
participant in each study arm. Any participant in the con-
trol study arm who meets clinical criteria for frailty
following baseline assessment will be provided access to
My-AHA interventions.
A suite of interventions will be available to all partic-
ipants in the intervention study arm. The selection of in-
terventions available to each participant will be
individually tailored to match the domain(s) identified as
being within the parameters for prefrailty. Interventions
are recommended where benefit to the participant is likely
and risk of harm is low. In this case, benefit is considered
to be evident where there is improvement across one or
more of the measures of outcome assessed at each of
the four assessment points. Assignment of interventions
Table 1
Operational criteria for identification of physical prefrailty in the My-AHA project
Physical domain
Prefrail 5 1 or 2 of the following criteria are met
1. Shrinking, evidenced by weight loss
(unintentional)
!4.5 kg unintentional in prior 12 months; or
at follow-up assessment ! 5% of body
weight in prior 12 months
Self-reported weight loss (not due to dieting
or fasting) in preceding 12 mo ! 4.5 kg
Follow-up: K5 (weight in previous year–
current measured weight)/(weight in
previous year). If K ! 0.05, meets weight
loss frailty criteria
2. Weakness Grip strength in lowest 20% at baseline adjusted for gender and BMI
Males BMI Grip strength (kg) Females BMI Grip strength (kg)
"24 "29 "23 "17
24.1–26 "30 23.1–26 "17.3
26.1–28 "30 26.1–29 "18
.28 "32 .29 "21
3. Poor endurance and energy Self-report of exhaustion as indicated by
responses to two questions on CES-D
scale
Using the CES–DDepression Scale, response
of “2” (a moderate amount of the time, 3–
4 days) or “3” (most of the time) to either
of the following 2 items: (a) I felt that
everything I did was an effort; and/or (b) I
could not get going.
4. Slowness Time to walk 4.00 m " slowest 20% adjusted for gender and standing height
Male Height (cm) Time to walk 4 m Female Height (cm) Time to walk 4m
"173 !6.13 sec "159 !6.13 sec
.173 !5.25 sec .159 !5.25 sec
5. Low physical activity level Energy expenditure per week below
established cutoff
Short version of the IPAQ questionnaire
assesses activity levels for walking,
moderate-intensity and vigorous-intensity
activities for work, transportation,
domestic chores, gardening, and leisure-
related activities.
IPAQ activity category
level 5 low
Abbreviations: My-AHA, My Active and Healthy Aging; IPAQ, International Physical Activity Questionnaire; CES-D, Center for Epidemiologic Studies
Depression Scale; BMI, body mass index.
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occurs based on algorithms developed to match the need
for intervention across each domain and participant pref-
erence (Supplementary Table S1). The data used by the al-
gorithms are designed so as to be ultimately incorporated
into the My-AHA application, enabling the system to
continuously update and modify intervention packages
for individuals as new information is fed into the system.
Data for the algorithms involve a combination of self-
report, sensor-based, and questionnaire-based information
(Supplementary Table S1), with this data being used to
determine the allocation of intervention type and load
across domains (Supplementary Table S2). This will result
in a “prescription” of interventions tailored to individual
participant needs. The intervention prescription will be a
maximum of 210 minutes per week (or average of 30 mi-
nutes per day); however, participants are able to undertake
additional interventions at their own choice. Recalculation
of the intervention package for each participant will occur
following assessment point, with intervention prescrip-
tions having an effective 6-month duration. Intervention
packages have been developed for physical, cognitive,
psychosocial, nutrition, and sleep domains. Participants
will undertake different intervention packages depending
on individual tailoring. The goal of this trial is not to
test the efficacy of a single intervention, but rather to
examine the efficacy of a multidimensional interventional
approach whereby each participant is prescribed an inter-
vention package matching their specific needs.
2.4.1. Physical interventions
Interventions have been selected to target the key phys-
ical markers of frailty: weight loss, physical weakness,
Fig. 1. Schematic of study design.
Table 2
Operational criteria for detection of clinically significant deficits cognitive and psychological function
Cognitive domain
Exclude if both of the following criteria are met
1. Evidence of lowered general
cognitive function
Mini–Mental State Examination test
(MMSE)
Age-adjusted MMSE " 23
2. Evidence of lower than age-
appropriate learning and recall of verbal
information
Hopkins Verbal Learning Test (HVLT) HVLT-total recall score " 24
Psychological domain
Exclude if any of the following criteria are met
1. Increased levels of anxiety and/or
lowered mood experienced over the
preceding week
Hospital and Depression Scale (HADS) HADS-a score ! 15 (severe symptoms)
HADS-d score ! 15 (severe symptoms)
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reduced energy, motor slowing, and reduced physical activ-
ity [5]. With falls being the most likely consequence of
increasing physical frailty [37], prevention of falls through
balance training to enhance gait pattern and postural control
is a key approach to be used in the My-AHA project. The
multicomponent physical interventions deployed in the
My-AHA project involve activities that combine strength
and balance training over an extended duration
(!5 months), with high-frequency repetition (performed
three times per week) for 30–45 minutes per session. Such
Table 3
My-AHA RCT inclusion and exclusion criteria for participant screening
Inclusion criteria
1. Age: over 60 yrs
2. Familiar with use of smartphones and/or tablet computers
3. Meet criteria for physical prefrailty (Table 1)
4. Ambulatory—able to stand and walk unassisted (Table 4)
5. Free of significant cognitive impairment (Table 2)
6. Free of clinically significant mood disturbance (Table 2)
7. Free of any acute or unstable medical conditions (Table 4)
8. Able to understand directions and participate in the protocol
9. Able to sign informed consent
Exclusion criteria Participant excluded if meets 1 or more of below:
Mobility problems 1. Unable stand and ambulate unassisted
2. Painful arthritis, spinal stenosis, amputation, or painful foot lesions that
limits balance and mobility,
Concurrent chronic disease independently contributing to frailty 1. Suffers from a significant neurodegenerative CNS disorder (e.g.,
dementia, Parkinson’s disease, multiple sclerosis, progressive
supranuclear palsy, amyotrophic lateral sclerosis, hydrocephalus,
Huntington’s disease, and prion diseases)
2. Affected by severe peripheral nervous system and/or neuromuscular
disorders, e.g., CIDP, myasthenia gravis, multiple sclerosis, and
polymyositis
Concomitant injury or disease known to impact independently cognitive,
psychological, or physical function
1. Clinical evidence or history of stroke (within 2 yrs)
2. Clinical evidence or history of transient ischemic attack (within 6months)
3. Significant head injury with loss of consciousness, skull fracture or
persisting cognitive impairment (2 years)
4. Epilepsy (a single prior seizure is considered acceptable)
5. If meets DSM-5 criteria for the following: major depressive disorder
(current), schizophrenia or other psychotic disorders (lifetime), bipolar
disorder (within the past 5 years), and substance (including alcohol)-
related disorders (within the past 2 years)
Presence of deficits that interfere with assessment validity 1. Have language deficits that impair testing
2. Have significant visual impairment
3. Have a significant hearing loss
Presence of other conditions or diseases that will compromise
participants ability to undertake interventions (especially physical)
1. Have clinically significant cardiovascular disease (e.g., hospitalization for
acute coronary syndrome, acute myocardial infarction or unstable,
angina; symptoms consistent with angina pectoris (within the
12 months), signs or symptoms of clinical heart failure within the
12 months, evidence of uncontrolled atrial fibrillation, a cardiac
pacemaker).
2. Preexisting or current signs or symptoms of respiratory failure (e.g.,
chronic obstructive pulmonary disease, bronchial asthma, lung fibrosis,
and other respiratory disease)
3. Untreated hypertension
4. Metastatic cancer or immunosuppressive therapy
5. Concurrent acute or chronic clinically significant immunologic, hepatic
(such as presence of encephalopathy or ascites), or endocrine disease (not
adequately treated).
Unacceptable Test/Laboratory Values 1. Postural hypotension (fall in systolic blood pressure of greater than
30 mmHg or fall in diastolic blood pressure of greater than 20 mmHg on
standing compared to sitting) at the time of screening. Participants who
present at the time of screening with postural hypotension yet have no
known history of postural hypotension, nor underlying medical condition
related to hypotension, may be rescreened
Abbreviations:My-AHA,MyActive and HealthyAging; RCT, randomized controlled trial; CNS, central nervous system; CIDP, chronic inflammatory demy-
elinating polyneuropathy; DSM5, Diagnostic and Statistical Manual of Mental Disorders 5th edition.
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physical interventions have been found to result in superior
outcomes compared with other exercise programs [38] and
that multicomponent exercise interventions display the
greatest reduction in falls rate and improvement in gait, bal-
ance, and strength performance in physically frail older
adults [39,40].
For the strength and balance domains, the OTAGO
home-based exercise program (OEP) [41] and the Fitness
and Mobility Exercise program [42] will be applied.
Following an initial training session with an exercise
instructor, the OEP will be deployed as a home-based ex-
ercise program used by older adults in their own homes
without supervision up to a maximum of three 30-
minute sessions per week. Participants will undertake
the OEP program one session per week. Fitness and
Mobility Exercise program is a group-based exercise
program which participants will complete a maximum
of a 1 hour session per week under the supervision of a
Table 4
Participant recruitment by study center
Region Country Study center
Total
n
Control
arm
Intervention
arm
Europe Italy University of
Torino
40 20 20
Germany Johanniter e.V. 100 50 50
Austria Johanniter
Osterreich
100 50 50
Spain IBV/Gesmed 80 40 40
UK St John
Ambulance
40 20 20
Belgium Johanniter
International
50 25 25
Sweden Johanniterjalpen 40 20 20
Australia Australia University of the
Sunshine Coast
50 25 25
Asia Japan Tohoku University 50 25 25
South Korea University of Seoul 50 25 25
Total 600 300 300
Table 5
Assessment battery
Domain Test name
Demographic Standardized questionnaire assessing age, gender, education level, residential status, falls history, prior mental activity, medical history, and
continence
Adherence Cognitive games (in My-AHA platform) time spent in game, time scheduled
FAME–calendar with diary
OTAGO–calendar with diary
VitalinQ–time spent/recipes used
Technology–duration and frequency of app use
Health World Health Organisation Quality of Life scale–OLD extension (WHO-QoL-OLD) [22]
Lawton-Brody Instrumental Activities of Daily Living (iADL) scale [23]
Physical Weight (kg)
Height (cm)
Grip strength
Center for Epidemiologic Studies Depression Scale (CES-D)–2 items [24]
Time to walk 4 m
International Physical Activity Questionnaire–Short Version (IPAQ-SV)
Dual-Task Performance
Timed up and Go test
Short Physical Performance Battery (SPPB)–Balance subtest, Sit-Stand subtest [25]
Activities-specific Balance Confidence (ABC) scale [26]
Physical Activity Enjoyment Scale (PACES) [27]
Cognitive Mini–Mental State Examination (MMSE) [28]
Hopkins Verbal Learning Test (HVLT) [29]
Spatial Span (SSP) from the Wechsler Memory Scale, 3rd edition [30]
Trail Making Test (TMT) [31]
24 item Victoria version Stroop test [31]
Digit Symbol coding subtest (DSC) from the Wechsler Adult Intelligence Scale [32]
Psychological Hospital Anxiety and Depression Scale (HADS) [33]
Social Lubben Social Network Scale, Short form (LSNS-R) [34]
University of California, Los Angeles Loneliness Scale–Revised [35]
Sleep Pittsburgh Sleep Quality Index (PSQI)
Nutrition BMI (derived from height/weight data in physical battery)
Self-Mini Nutritional Assessment (Self-MNA) [36]
Technology Evaluation of usability scale (SUS)
DART questionnaire
Computer literacy scale (CLS)
User experience questionnaire (UEQ)
Measures of prefrailty/frailty criteria
Abbreviations: My-AHA, My Active and Healthy Aging; FAME, Fitness and Mobility Exercise program; BMI, body mass index.
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physical exercise instructor (appropriately qualified and
trained fitness instructors, physical therapists, or occupa-
tional therapists). Physical intervention type and fre-
quency (dose) is determined on an individual basis by
the intervention algorithm (Supplementary Tables S1
and S2) with the maximum physical intervention
schedule of two OTAGO sessions and one Fitness and
Mobility Exercise program session per week (total
120 minutes per week).
2.4.2. Cognitive interventions
Cognitive interventions in the My-AHA project will
comprise working memory training (N-back task) and
cognitive bias modification therapy using attention bias
modification (ABM) tasks. As with physical interventions,
the type of cognitive intervention offered to each participant
will be individually tailored as determined by their individ-
ual areas of strength and weakness identified at each assess-
ment point (see Supplementary Tables S1 and S2).
To achieve maximum adherence, self-efficacy, and
engagement, the n-back task will use graded difficulty
whereby task difficulty is continuously adjusted to match
participant level of performance. The level of n is main-
tained when participants give between 75% and 89% cor-
rect responses. Two versions of the n-back task will be
used: a letter-based and a visuospatial version. For both
letter-based and visuospatial n-back tasks, eight combina-
tions of presentation time and interstimulus intervals will
be used. A session comprises 15 blocks of n-back training
(approximately 15 minutes). At the end of the session, par-
ticipants are provided with an overview of their perfor-
mance, for example, correct hits and misses, as well as
average level of n. The training will be delivered via the
My-AHA app directly but can also be installed on the par-
ticipant’s home computer and operated with a keyboard or
computer mouse.
Cognitive bias modification therapy trains anxious or
depressed individuals to disengage from threat-related
stimuli and redirecting their attention toward other “posi-
tive” stimuli [43]. There are two common variants of
cognitive bias modification therapy, namely ABM and
interpretative bias modification, both reported to be effec-
tive in reducing anxiety and depression pathology [44].
ABM is a modified computerized visual-probe procedure
in which participants learn to direct their attention toward
relatively positive stimulus, which can be a word or a pic-
ture, and away from threat-related stimuli. A session of
ABM comprises 96 trials, and participants are recommen-
ded to complete three 5-minute-long sessions per week for
28 sessions in total.
2.4.3. Psychosocial interventions
Three social interventions will be implemented in the
My-AHA project: group activity interventions, group sup-
port interventions, and a social media platform. Group ac-
tivity interventions will increase participant engagement in
social interaction by provision of targeted group-based ac-
tivities including: group autobiographical recall activity
(www.Activ84Health.eu) in which participants are able to
visit a location from their past (using google street view
imagery) and guide others through the area while
describing their memories and experiences, group cooking
classes, and group excursion-based activities (e.g., visiting
a museum). The My-AHA platform will match partici-
pant’s preferences for type of activity and will create digi-
tal activity groups for participants with common
preferences. The My-AHA platform then matches appro-
priate group activity proposals and presents the demand
for specific group activities to secondary stakeholders
(e.g., community organizations, local councils, support
groups, and so on) as providers of group activities. Group
support interventions will provide an opportunity for par-
ticipants to find targeted help and support (e.g., bereave-
ment support, disease support such as cancer support
groups). My-AHA participants can set corresponding pa-
rameters in their profile to indicate their need for support.
The My-AHA platform will match support groups to indi-
vidual participants, based on the parameters and prefer-
ences set by the participant. The social media platform
will encompass the exchange and sharing of information
as well as communication with other participants. It will
provide a digital space for participants to interact with
each other and share information, opinions, and recommen-
dations.
2.4.4. Nutritional interventions
Nutritional interventions will be implemented in a nutri-
tion application for mobile devices. The interventions to be
deployed include the following: individual meal plan gener-
ation and tailored nutritional advice and education. In the
My-AHA nutritional application, meal plans and recommen-
dations will be generated and presented to the user. The meal
planning system takes into account anthropometric data,
lifestyle, activity level, and nutritional status of the partici-
pant as well as user preferences when creating individually
tailored meal plans. The recommendations are official
guidelines, determined by official nutritional institutions in
each participating country. Recommendations will be
compared with the recipes in the database and adjusted for
participant preferences (such as known allergies, lifestyle
(e.g., vegetarian), and/or preferred cuisine).
Participants will also be able to receive nutritional advice
based on the food intake they log into their food diary [45].
They will be educated on what they eat and be provided
advice on how to improve their nutritional intake to meet
their requirements.
2.4.5. Sleep interventions
Sleep interventions will be an optional offering to partic-
ipants and will comprise advice on methods to enhance sleep
duration and quality. Participants will be provided with two
advice options: passive body heating or light exposure. For
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passive body heating, participants will be provided detailed
advice on using a 30-minute-long hot bath (40–41#C) 1.5–
2 hours before going to bed, with 50–100 mL of water to
be consumed following the bath. The recommended
schedule for passive body heating is in blocks of 5 consecu-
tive days, followed by a single rest day. Light exposure will
be recommended for participants experiencing either
advanced sleep phase or delayed sleep phase. For advanced
sleep phase, participants will recommended to undertake
bright light (460 nm light blue, 2000–10,000 lux) or sunlight
exposure of 1–2 hours duration between 17:00 and
19:00 hours each day. For delayed sleep phase, participants
will be recommended to undertake bright light (460 nm light
blue, 2000–10,000 lux) or sunlight exposure of 1–2 hours
duration between 07:00–09:00 hours each day.
2.5. Assessment measures
At baseline, 6, 12, and 18 months, each participant will
undergo a comprehensive assessment (Table 5 and Fig. 1).
The assessment battery includes measures required to assess
for the presence of frailty/prefrailty as well as measures sen-
sitive to changes in cognitive, physical, and psychosocial
function.
2.6. Statistical considerations
Between-group comparisons of continuous measures us-
ing analysis of covariance will be made for each of the five
main outcomes in the main wave: well-being (World Health
Organisation Quality of Life scale – OLD extension [WHO-
QOL-OLD]), physical fitness, cognitive function, psycho-
logical state, and social connectedness. Each of the final
four outcomes will be based on compound scores of the rele-
vant outcome variables, weighted by the first component of a
principal component analysis of all variables in each
domain. To correct for multiple comparisons, we will use a
Bonferroni adjustment of alpha5 0.05/55 0.01, and signif-
icant confounding variables (e.g., age, gender, education,
and so forth) will be corrected for. An intention-to-treat
approach will be used for all between-group analyses, and
we project a drop-out rate of 30% over the 18 months of
the RCT. As lifestyle effects are typically weak but likely
to have a significant impact on health in the wider popula-
tion, we power generically to detect at least weak effects
(f5 0.1). Assuming a correlation among the repeat measures
of 0.5 and the sample size of n5 600 yields actual power of
93.4%, indicating that the trial in the main wave is well pow-
ered with the planned participant recruitment.
2.7. Ethics and safety aspects
The My-AHA RCT has been approved by the coordi-
nating center ethics committee (University of Torino) and
will be approved by the relevant ethics boards for each of
the RCT trial sites. Participants gave written fully informed
consent before enrollment in the study. Ethical principles as
specified under the Helsinki Declaration will be adhered to
at each RCT site. Safety issues of the interventions are care-
fully considered with a project safety committee meeting
regularly for the assessment and management of any occur-
ring adverse events.
2.8. Data management process
A purpose-built e-portal (My-AHA platform) has been
developed for use by participants and site investigators.
TheMy-AHA platform enables the connection with multiple
third-party applications that provide physiological data
through sensors (physical activity duration and intensity,
sleep quality and duration, weight, heart rate, blood pressure,
and glucose levels) as well as the manual input of additional
data. Through the My-AHA interface, participants are able
to connect with external e-systems (e.g., nutritional plat-
forms provided by VitalinQ) as well as multiple intervention
platforms. The My-AHA portal represents a common inter-
face between each individual participant and multiple
external connections, with participant data being stored
securely within the platform.
2.9. Study progress
Pilot testing of the My-AHA platform and all ancillary
systems was undertaken in 2017 with a small number of par-
ticipants in Europe, with additional examination and modifi-
cations to the system based on usability testing undertaken in
Living Labs held in Germany. On the basis of the pilot
testing and living lab data, final modifications of the My-
AHA platform are being completed ahead of the scheduled
commencement of the RCT in early 2018 with each partici-
pant to complete the 18-month trial by late 2019.
3. Results of alpha wave
The alpha wave of the My-AHA protocol was planned
as a pilot study to evaluate, in a limited sample of represen-
tative participants, the portability and usability of the
My-AHA platform, including assessment protocols, ques-
tionnaires, and technical aspects of the platform. No inter-
vention was delivered as part of the alpha wave. Sites
participating in the alpha wave were Torino (Italy), Valencia
(Spain), Vienna (Austria), and Kempten (Germany). The
alpha wave commenced on February 1, 2017 following
approval from the Ethics Committee in Torino, with the
alpha wave trial concluding June 30, 2017.
A sample of 97 participants (57 female, 40 male) under-
went screening procedures. In accordance with Fried et al.
[5] criteria, 20 prefrail participants (12 female, 8 male;
mean age 70.1 6 7.4 years) were recruited into the 3-
month alpha wave trial. Following baseline assessment, par-
ticipants were individually examined by the local principal
investigator on a monthly basis. The assessment protocol
was in keeping with the RCT protocol described above
with minor deviations.
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All enrolled participants in the alpha wave reported the
protocol to be well accepted. Minor technical problems
relating to connections between devices and the middleware
software were reported by three participants. Supplementary
Fig. S1 displays the output from the My-AHA platform for
physical activity data (daily steps) from one participant
enrolled in the alpha wave through the use of the SmartCom-
panion application. Supplementary Fig. S2 displays the fre-
quency of cognitive exercises performed by a single
participant on one of the cognitive platforms tested in the
alpha wave. Participant and investigator feedback regarding
the graphical interface for providing activity feedback were
collected and incorporated into platform revisions. As ex-
pected, no significant differences were detected between
participants neuropsychological test performances and Fried
criteria over the course of the 3-month alpha wave trial. The
results of alpha wave trial indicate that the My-AHA plat-
form is suitable for implementation in the full RCT study.
4. Discussion
The My-AHA project is designed to undertake a multido-
main assessment and intervention of prefrail levels of phys-
ical, cognitive, social, or psychological impairment in older
adults to prevent or delay the development of clinical frailty.
At present, there is little understanding of the antecedent risk
factors for clinical frailty; hence, a key aim of this project is to
identify risk markers of prefrail levels of impairment so as to
optimize targeted interventions. Frailty is a significant risk
factor for the development of multiple age-related diseases
[1–5] and confers a significantly increased risk for poor
health outcomes, incident disability, hospitalization, and
mortality [7,10–14]. Through the use of in-home ICT-based
solutions, theMy-AHAproject will implement and trial an in-
tegrated system of assessment and intervention that will
deliver individually tailored solutions for older adults at risk
of developing frailty. The platform developed is designed to
be technology-agnostic, enabling the integration of new de-
vices and sensor platforms as they emerge. Furthermore, the
platform has been developed across multiple languages (En-
glish, Italian, Spanish, German, Dutch, Korean, and Japanese)
to enable rapid deployment across multiple countries.
At the conclusion of the RCT, we expect to have devel-
oped evidence-based criteria for the detection and diagnosis
of prefrailty across multiple domains as well as have
evidence-based intervention efficacy data relating to the ca-
pacity of individually tailored interventions to delay, pre-
vent, or treat clinical frailty in older adults.
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RESEARCH IN CONTEXT
1. Systematic review: Frailty increases risk of negative
outcomes including death in older adults. The My
Active and Healthy Aging (My-AHA) project is a
multisite, multinational longitudinal randomized
control trial to test the efficacy of delivering informa-
tion and communications technology (ICT) sup-
ported in-home multidomain interventions tailored
to individual risk profiles for older adults with pre-
frailty.
2. Interpretation: Prefrail adults aged 60 years and older
will participate in an 18-month-long randomized
controlled trial. Participants will be randomly allo-
cated to a standard care control group or My-AHA
intervention group. Individual frailty risk across
physical, cognitive, mood, social, and nutrition do-
mains will be monitored at six monthly intervals with
individually tailored interventions being provided to
each participant in the intervention group. The effi-
cacy of the My-AHA intervention platform will be
evaluated at the completion of the randomized
controlled trial.
3. Future directions: This study expands on current con-
ceptualizations of frailty as physical disease and in-
corporates the notion of frailty as a
multidimensional disease state. The My-AHA ran-
domized controlled trial study will assess the efficacy
of providing ICT-based in-home tailored in-
terventions to reduce the incidence of frailty in older
adults at risk of developing frailty. This may lead to
future implementation of new technologies to assist
older adult remain in their own home as they age
through reduction of the incidence of frailty in the
aging community.
References
[1] Blair SN, Kohn KW, Barlow CE, Paffenbarger RS, Gibbons LW,
Macera CA. Changes in physical fitness and all cause mortality: a
M.J. Summers et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 252-262 261
prospective study of healthy and unhealthy men. JAMA 1995;
273:1093–8.
[2] Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling
the concepts of disability, frailty, and comorbidity: implications for
improved targeting and care. J Gerontol Ser Biol Sci Med Sci 2004;
59:255–63.
[3] GillickM. Pinning down frailty. J Gerontol Ser Biol Sci Med Sci 2001;
56A:M134–1135.
[4] Hammerman D. Toward an understanding of frailty. Ann Intern Med
1999;130:945–50.
[5] Fried LP, Tangen CM,Walston J, NewmanAB, Hirsch C, Gottdiener J,
et al. Frailty in older adults: evidence for a phenotype. J Gerontol Ser
Biol Sci Med Sci 2001;56:M146–56.
[6] Panza F, Solfrizzi V, Barulli MR, Santamato A, Seripa D, Pilotto A,
et al. Cognitive frailty: a systematic review of epidemiological and
neurobiological evidence of an age-related clinical condition. Rejuve-
nation Res 2015;18:389–412.
[7] Soong J, Poots AJ, Scott S, Donald K, Woodcock T, Lovett D, et al.
Quantifying the prevalence of frailty in English hospitals. BMJ
Open 2015;10:e008456.
[8] Varadhan R,Walston J, Cappola AR, CarlsonMC,Wand GS, Fried LP.
Higher levels and blunted diurnal variation of cortisol in frail older
women. J Gerontol Ser Biol Sci Med Sci 2008;63:190–5.
[9] Brown I, Renwick R, Raphael D. Frailty: constructing a common
meaning, definition, and conceptual framework. Int J Rehabil Res
1995;18:93–102.
[10] Buchner DM, Wagner EH. Preventing frail health. Clin Geriatr Med
1992;8:1–17.
[11] Kojima G, Iliffe S, Jivraj S, Walters K. Association between frailty and
quality of life among community-dwelling older people: a systematic re-
view andmeta-analysis. J Epidemiol CommunityHealth 2016;70:716–21.
[12] Ory MG, Schechtman KB, Miller JP, Hadley EC, Fiatarone MA,
Province MA, et al. Frailty and injuries in later life: the FICSIT trials.
J Am Geriatr Soc 1993;41:283–96.
[13] Shamliyan T, Talley KM, Ramakrishnan R, Kane RL. Association of
frailty with survival: a systematic literature review. Ageing Res Rev
2013;12:719–36.
[14] Woodhouse KW. Frailty and aging. Age Ageing 1997;26:245–6.
[15] Campbell AJ, Buchner DM. Unstable disability and the fluctuations of
frailty. Age Ageing 1997;26:315–8.
[16] Drey M, Pfeifer K, Sieber CC, Bauer JM. The fried frailty criteria as
inclusion criteria for a randomized controlled trial: personal experi-
ence and literature review. Gerontology 2011;57:11–8.
[17] Albert MS, DeKosky ST, Dickson D, Dubois B, FeldmanHH, FoxNC,
et al. The diagnosis of mild cognitive impairment due to Alzheimer’s
disease: recommendations from the National Institute on Aging-Alz-
heimer’s Association workgroups on diagnostic guidelines for Alz-
heimer’s disease. Alzheimer’s Demen 2011;7:270–9.
[18] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG,
Kokmen E. Mild cognitive impairment: clinical characterization and
outcome. Arch Neurol 1999;56:303–8.
[19] Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L,
Wahlund LO, et al. Mild cognitive impairment - beyond controversies,
towards a consensus: report of the International Working Group on
Mild Cognitive Impairment. J Intern Med 2004;256:240–6.
[20] Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S,
et al. Preclinical Alzheimer’s disease: Definition, natural history, and
diagnostic criteria. Alzheimer’s Demen 2016;12:292–323.
[21] Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC,
Devereaux PJ, et al. CONSORT 2010 Explanation and Elaboration:
updated guidelines for reporting parallel group randomised trials.
BMJ 2010;340.
[22] World Health Organization. The WHOQOL-OLD Module - Manual.
EuropeanOffice, Copenhagen:Word Health Organisation; 2006. p. 61.
[23] Lawton MP, Brody EM. Assessment of older people: self-maintaining
and instrumental activities of daily living. Gerontologist 1969;9:179–86.
[24] Radloff LS. The CES-D scale: a self-report depression scale for
research in the general population. Appl Psychol Meas 1977;
1:385–401.
[25] Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF,
Blazer DG, et al. A short physical performance battery assessing lower
extremity function: association with self-reported disability and pre-
diction of mortality and nursing home admission. J Gerontol 1994;
49:M85–94.
[26] Powell LE, Myers AM. The activities-specific balance confidence
(ABC) scale. J Gerontol Ser Biol Sci Med Sci 1995;50a:M28–34.
[27] Kendzierski D, DeCarlo K. Physical activity enjoyment scale: two
validation studies. J Sport Exerc Psychol 1991;13:50–64.
[28] Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A prac-
tical method for grading the cognitive state of patients for the clinician.
J Psychiatr Res 1975;12:189–98.
[29] Brandt J. The Hopkins verbal learning test: development of a new
memory test with six equivalent forms. Clin Neuropsychol 1991;
5:125–42.
[30] Wechsler D. Wechsler Memory Scale - Third Edition (WMS-III):
Administration and Scoring Manual. San Antonio, TX: The Psycho-
logical Corporation; 1997.
[31] Lezak MD, Howieson DB, Bigler ED, Tranel D. Neuropsychological
Assessment. 5th ed. Oxford: Oxford University Press; 2012.
[32] Wechsler D.Wechsler Adult Intelligence Scale - Third Edition (WAIS-
III): Administration and Scoring Manual. San Antonio, TX: The Psy-
chological Corporation; 1997.
[33] Snaith RP, Zigmond AS. The Hospital Anxiety and Depression Scale
(HADS): Manual. London, UK: GL Assessment Ltd; 1994.
[34] Lubben JE. Assessing social networks among elderly populations.
Fam Community Health 1988;11:42–52.
[35] Russell D, Peplau LA, Cutrona CE. The revised UCLA Loneliness
Scale: Concurrent and discriminant validity evidence. J Personal So-
cial Psychol 1980;39:472–80.
[36] Nestl"e Nutrition Institute. Self-MNA: Mini Nutritional Assessment -
for Adults 65 Years of Age and Older. Vevey, Switzerland: Soci"et"e
des Produits Nestl"e S.A; 2012.
[37] de Vries OJ, Peeters GM, Lips P, Deeg DJ. Does frailty predict
increased risk of falls and fractures? A prospective population-based
study. Osteoporos Int 2013;24:2397–403.
[38] Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C,
Vandervoort AA, et al. The effectiveness of exercise interventions for the
management of frailty: a systematic review. J Aging Res 2011;2011:19.
[39] Cadore EL, Pinto RS, Bottaro M, Izquierdo M. Strength and endurance
trainingprescription inhealthyand frail elderly.AgingDis 2014;5:183–95.
[40] Cadore EL, Rodr"ıguez-Ma~nas L, Sinclair A, Izquierdo M. Effects of
different exercise interventions on risk of falls, gait ability, and balance
in physically frail older adults: A systematic review. Rejuvenation Res
2013;16:105–14.
[41] Gardner MM, Buchner DM, Robertson MC, Campbell AJ. Practical
implementation of an exercise-based falls prevention programme.
Age Ageing 2001;30:77–83.
[42] Eng JJ. Fitness and mobility exercise program for stroke. Top Geriatr
Rehabil 2010;26:310–23.
[43] Wadlinger HA, Isaacowitz DM. Looking happy: the experimental
manipulation of a positive visual attention bias. Emotion (Washington,
DC) 2008;8:121–6.
[44] MacLeod C. Cognitive bias modification procedures in the manage-
ment of mental disorders. Curr Opin Psychiatry 2012;25:114–20.
[45] Mensink RP, Katan MB. Effect of a diet enriched with monounsatu-
rated or polyunsaturated fatty acids on levels of low-density and
high-density lipoprotein cholesterol in healthy women and men. N
Engl J Med 1989;321:436–41.
M.J. Summers et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 4 (2018) 252-262262
View publication stats
